HOME >> BIOLOGY >> NEWS
Experimental therapy stops allergic reactions in mice

Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) have devised a new, experimental approach to treating allergic diseases. In mice, the scientists used a genetically engineered molecule to connect two receptors on the key immune system cells that cause allergic reactions. Cross-linking these receptor molecules short-circuited the type of allergic reaction that leads to asthma, allergic rhinitis, and even the potentially deadly anaphylaxis caused by food allergy.

This work represents an entirely new approach to treating allergic diseases, says NIAID Director Anthony S. Fauci, M.D. The prevalence of allergic disease has increased significantly in recent decades, and there simply are not many promising therapeutic strategies out there. We hope that NIAIDs continued support of research into the mechanisms of allergy will lead to other innovative concepts like this one.

This research does what science is supposed to do, says Marshall Plaut, M.D., chief of NIAIDs Allergic Mechanisms Section. The researchers succeeded in translating a scientific observation into a clever therapeutic idea. Details of this work, performed by a team of scientists at the University of California at Los Angeles (UCLA) and the University of New Mexico, appear in the May issue of Nature Medicine.

The scientists designed and created a molecule called GE2 that acts on two types of immune system cells central to allergic reactions: mast cells and basophils. In people with allergies, these cells respond to ordinarily harmless substances, such as pollen or peanut proteins, by releasing chemicals such as histamine that trigger the symptoms of allergic reactions. Histamine, for example, causes swelling, sneezing, itching, and irritation.

GE2 binds to receptor molecules on mast cells and basophils that control the release of histamine. One of these receptor molecules is like a gas pedal: it makes the allergic reaction go.
'"/>

Contact: Jeff Minerd
jminerd@niaid.nih.org
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
30-Apr-2002


Page: 1 2

Related biology news :

1. Experimental drug shown to block mutant protein causing blood disease
2. Experimental smallpox DNA vaccine protects primates from lethal monkeypox
3. Experimental smallpox vaccine protects against monkeypox in nonhuman primates
4. Experimental Biology 2004 - Translating the Genome
5. Experimental Biology 2004 meets in Washington, D.C. April 17-21
6. Experimental hantavirus vaccine elicits strong antibody response in primates
7. Experimental cancer drugs may halt events that lead to cardiac hypertrophy and heart failure
8. Experimental Biology 2003 meets in San Diego April 11-15
9. Experimental Biology 2003 meets in San Diego April 11-15
10. Experimental gene switch increases lifespan with no ill effects
11. APS awards 44 minority travel fellowships to the Experimental Biology 2002 meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/27/2019)... ... April 26, 2019 , ... ... on Thursday, April 25. More than 30 student venture teams, representing nearly 150 ... more than $75,000. , The top five teams in the College League ...
(Date:4/25/2019)... ... April 24, 2019 , ... NDA Partners Chairman Carl Peck, MD ... of experience in the development of drug and genomic diagnostic products for therapeutic indications ... joining NDA Partners, Dr. Maddala served as Vice President of Biometrics at GRAIL, Inc., ...
(Date:4/18/2019)... , ... April 18, 2019 , ... ... trials have emerged as a popular trial design that have the potential to ... been fully adopted by many sponsors due to the complexity of regulations, potential ...
Breaking Biology News(10 mins):
(Date:4/8/2019)... Utah and BOSTON (PRWEB) , ... April 08, ... ... delivering cloud-based enterprise-class unified communications and collaboration solutions, announced today the launch of ... integration to an unprecedented range of business and contact-orientated applications while using CT ...
(Date:4/8/2019)... Zealand (PRWEB) , ... April 09, 2019 , ... ... infectious disease, the innovative non-profit research center Chan Zuckerberg Biohub (CZ Biohub) has ... study of antibody repertoires is part of CZ Biohub’s efforts to establish new ...
(Date:4/4/2019)... ... April 03, 2019 , ... LeadingBiotech, an exclusive event ... today announces its Boston CEO conference to be held May 28-29, 2019 at ... opportunities with high-level panels and discussions from past, present and future change-makers. ...
(Date:3/27/2019)... ... March 26, 2019 , ... A leader in the field of Regenerative Veterinary ... the United States and Canada since 2004. The primary indications for VetStem Regenerative ... in the dog, cat, and horse. Recently, VetStem teamed up with the world-renowned ...
Breaking Biology Technology:
Cached News: